CN112569457B - Continuous administration cyst tube system - Google Patents
Continuous administration cyst tube system Download PDFInfo
- Publication number
- CN112569457B CN112569457B CN202011451940.4A CN202011451940A CN112569457B CN 112569457 B CN112569457 B CN 112569457B CN 202011451940 A CN202011451940 A CN 202011451940A CN 112569457 B CN112569457 B CN 112569457B
- Authority
- CN
- China
- Prior art keywords
- saccular
- blind end
- drainage tube
- medicine
- flow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010011732 Cyst Diseases 0.000 title description 9
- 208000031513 cyst Diseases 0.000 title description 9
- 239000003814 drug Substances 0.000 claims abstract description 51
- 239000012530 fluid Substances 0.000 claims abstract description 22
- 229940079593 drug Drugs 0.000 claims abstract description 16
- 239000000463 material Substances 0.000 claims abstract description 8
- 230000010412 perfusion Effects 0.000 claims abstract description 7
- 238000007789 sealing Methods 0.000 claims abstract description 4
- 238000010255 intramuscular injection Methods 0.000 claims description 11
- 238000010254 subcutaneous injection Methods 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 238000010253 intravenous injection Methods 0.000 claims description 9
- 239000000741 silica gel Substances 0.000 claims description 9
- 229910002027 silica gel Inorganic materials 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 claims description 3
- 238000002513 implantation Methods 0.000 claims description 3
- 239000007927 intramuscular injection Substances 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 239000007929 subcutaneous injection Substances 0.000 claims description 3
- 239000007943 implant Substances 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000007547 defect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
Abstract
The invention relates to a continuous administration sac tube system, which comprises a sac blind end, a flow limiting channel and a drainage tube, wherein the sac blind end is made of an elastically expandable material and can be buried under the skin; the flow limiting channel is connected between the saccular blind end and the drainage tube in a sealing way; the saccular blind end is used for storing fluid medicines and continuously pouring the fluid medicines to a treatment target point through the flow limiting channel and the drainage tube; the flow restricting channel is used for limiting the flow rate and the flow rate of the fluid medicine flowing out of the saccular blind end, so that the fluid medicine injected into the saccular blind end is temporarily reserved in the saccular blind end, and then the saccular blind end is inflated, so that continuous perfusion of the fluid medicine from the saccular blind end to the opening end of the drainage tube is maintained.
Description
Technical Field
The invention relates to the technical field of medical appliances, in particular to a continuous administration cyst tube system.
Background
At present, the traditional administration mode of the chemotherapeutic medicine is mainly intravenous injection, and the method can not accurately kill tumors, so the method has the defects of low efficiency, large side effect and the like. Topical administration is a better improvement to solve the above problems, including: local injection of disposable medicine, local administration by multiple punctures, local injection through a drainage tube, and the like. However, the above-mentioned topical administration methods all have respective drawbacks, which limit their clinical application.
Disadvantages of various topical methods of administration include: the disposable local injection of the medicine has low total dosage and short action time due to limited internal space; CT assistance and higher technical level are needed for the local administration of multiple punctures, the risk is high, and the popularization is difficult; local injection through the drainage tube easily causes in-vitro bacteria to enter the body through the outer opening of the drainage tube, and the risk of deep infection is extremely high. Therefore, the development of a new local drug delivery device to avoid the above-mentioned drawbacks is of great clinical importance.
Disclosure of Invention
The invention aims to provide a novel continuous administration sac tube system so as to solve the problems of small drug loading, short acting time, high risk of puncture operation, easiness in causing deep infection and the like in a local administration scheme in the prior art.
The invention aims to solve the defects in the prior art and provides a novel continuous administration sac tube system which comprises a sac-like blind end, a current limiting channel and a drainage tube, wherein the sac-like blind end is made of an elastically expandable material and can be buried under the skin; the flow limiting channel is connected between the saccular blind end and the drainage tube in a sealing way; the saccular blind end is used for storing fluid medicines and continuously pouring the fluid medicines to a treatment target point through the flow limiting channel and the drainage tube; the flow-limiting channel is used for limiting the flow rate and the flow quantity of the fluid medicine flowing out of the saccular blind end so that the fluid medicine injected into the saccular blind end is temporarily reserved in the saccular blind end, and then the saccular blind end is expanded, so that continuous perfusion of the fluid medicine from the saccular blind end to the opening end of the drainage tube is maintained.
The therapeutic target comprises the position around the tumor or the infection focus in the human body.
The open end of the drainage tube is implanted in a therapeutic target point at the deep part of the human body.
After the saccular blind end is buried subcutaneously, the medicine is allowed to be injected into the saccular blind end buried subcutaneously by a simple subcutaneous, intramuscular or intravenous injection technique.
Preferably, the saccular blind end allows the use of a conventional intramuscular, subcutaneous or intravenous injection needle to inject the drug into the subcutaneously buried saccular blind end.
One or more saccular blind ends are arranged.
The open end is provided with one or more.
The saccular blind end, the flow limiting channel and the drainage tube are made of elastic silica gel.
The saccular blind end can store 10ml to 400ml of medicine.
The restricted flow channel allows a restricted flow rate of fluid drug from the saccular blind end of 0.5 ml/day to 10 ml/day with an average administration period of 1 week to 1 year.
Advantageous effects
Compared with the prior art, the invention has the beneficial effects that:
according to the continuous administration saccular pipe system, one end of the traditional silica gel drainage pipe is made into an expanded saccular blind end and is used for being buried under the skin to store medicines and accept in-vitro medicine injection, and in the application process, more medicines can be contained in the saccular blind end buried under the skin, so that the problem of small medicine carrying capacity of the disposable medicine local injection is solved; the continuous administration sac tube system can be used for repeated administration, and the current-limiting channel can maintain continuous perfusion of the medicine, so that the problem of short acting time faced by local injection of the disposable medicine is avoided; when the continuous administration cyst tube system disclosed by the invention is used, the puncture operation for local administration is similar to the conventional subcutaneous, intramuscular or intravenous injection operation, CT assistance is not needed, and the problems of high puncture operation difficulty and high risk faced by repeated puncture local administration are avoided; the saccular blind end of the continuous administration saccular pipe system is buried under the skin, no external part exists, and the risk of deep infection caused by external bacteria entering the body through the external port of the drainage pipe is reduced.
Drawings
The accompanying drawings are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate and do not limit the invention.
Fig. 1 is a schematic view of the overall structure of a continuous administration balloon system according to the present invention.
Detailed Description
The present invention is described in more detail below to facilitate an understanding of the present invention.
As shown in fig. 1, the continuous administration balloon catheter system of the invention comprises a balloon-shaped blind end 1, a flow limiting channel 2 and a drainage tube 3, wherein the balloon-shaped blind end is made of an elastically expandable material and can be buried under the skin; the flow limiting channel 2 is connected between the saccular blind end 1 and the drainage tube 3 in a sealing way; the saccular blind end is used for storing fluid medicines and continuously pouring the fluid medicines to a treatment target point through the flow limiting channel 2 and the drainage tube 3; the restricted flow channel 2 is used for limiting the flow rate and flow rate of the fluid medicine flowing out of the saccular blind end, so that the fluid medicine injected into the saccular blind end is temporarily reserved in the saccular blind end, and then the saccular blind end is inflated, so that continuous perfusion of the fluid medicine from the saccular blind end to the opening end 4 of the drainage tube is maintained.
The therapeutic target comprises the position around the tumor or the infection focus in the human body.
The open end of the drainage tube is implanted in a therapeutic target point at the deep part of the human body.
After the saccular blind end is buried subcutaneously, the medicine is allowed to be injected into the saccular blind end buried subcutaneously by a simple subcutaneous, intramuscular or intravenous injection technique.
Preferably, the saccular blind end allows the use of a conventional intramuscular, subcutaneous or intravenous injection needle to inject the drug into the subcutaneously buried saccular blind end.
Further preferably, one or more of the capsule-like blind ends are provided and one or more of the open ends are also provided to effect drug loading and delivery of one or more drugs.
The saccular blind end, the flow limiting channel and the drainage tube are made of elastic silica gel.
The continuous administration cyst tube system is improved on the basis of a traditional silica gel drainage tube, only the internal part of the traditional drainage tube is reserved, one end of the shallow part of the drainage tube is made into an inflatable cyst blind end by elastic silica gel, a narrow flow limiting channel is reserved between the cyst blind end and the drainage tube, the flow limiting channel can only enable liquid to slowly flow through (the cyst blind end stores about 10-400ml, the flow limiting channel enables the flow rate to be limited to 0.5-10 ml/day, the average administration period is about 1 week-1 year), so that the medicine injected into the inflatable blind end is temporarily reserved, and then the cyst blind end is inflated, so that continuous perfusion of the medicine from the blind end to the open end is maintained. The user can implant the open end of the invention into a deep treatment target (such as around a tumor or around an infection focus) according to the implantation mode of the traditional drainage tube, and then the saccular blind end of the invention is buried under the skin. After operation, the medicine can be injected into the saccular blind end buried under the skin by using a common intramuscular injection needle, a subcutaneous injection needle or an intravenous transfusion needle and adopting a simple subcutaneous, intramuscular or intravenous injection technology; the medicine injected into the saccular blind end can enter a deep treatment target point through the drainage tube, so that the effect of accurate treatment is achieved.
The materials of the saccular blind end, the flow limiting channel and the drainage tube are not limited to silica gel materials, and other materials which can be used for implantation of human bodies can be used as substitute materials of silica gel.
The foregoing describes preferred embodiments of the present invention, but is not intended to limit the invention thereto. Modifications and variations to the embodiments disclosed herein may be made by those skilled in the art without departing from the scope and spirit of the invention.
Claims (1)
1. The continuous administration balloon catheter system is characterized in that the continuous administration balloon catheter system is improved on the basis of a traditional silica gel drainage tube, only the internal part of the traditional drainage tube is reserved, one end of the shallow part of the drainage tube is made into an inflatable balloon-shaped blind end, a narrow flow limiting channel is reserved between the balloon-shaped blind end and the drainage tube, so that the medicine injected into the inflatable blind end is temporarily reserved, and then the balloon-shaped blind end is inflated, so that continuous perfusion of the medicine from the blind end to the open end is maintained; the saccular blind end is in natural transitional connection with the flow limiting channel without any connecting component;
the continuous administration saccular pipe system comprises a saccular blind end, a current limiting channel and a drainage pipe, wherein the saccular blind end is made of an elastically expandable material and can be buried under the skin; the flow limiting channel is connected between the saccular blind end and the drainage tube in a sealing way; the saccular blind end is used for storing fluid medicines and continuously pouring the fluid medicines to a treatment target point through the flow limiting channel and the drainage tube; the flow limiting channel is used for limiting the flow rate and the flow quantity of the fluid medicine flowing out of the saccular blind end so as to ensure that the fluid medicine injected into the saccular blind end is temporarily reserved in the saccular blind end, and then the saccular blind end is expanded, so that the continuous perfusion of the fluid medicine from the saccular blind end to the opening end of the drainage tube is maintained;
the saccular blind end, the flow limiting channel and the drainage tube are made of elastic silica gel;
the saccular blind end can store 10ml to 400ml of medicine;
the flow-limiting channel enables the flow-limiting rate of the fluid medicine flowing out of the saccular blind end to be 0.5 ml/day to 10 ml/day, and the average administration period is 1 week to 1 year;
one or more saccular blind ends are arranged;
one or more open ends are arranged;
the treatment target comprises the positions around tumors or infection focus in a human body;
the opening end of the drainage tube is implanted in a therapeutic target point at the deep part of the human body;
after the saccular blind end is buried under the skin, the medicine is allowed to be injected into the saccular blind end buried under the skin by a simple subcutaneous, intramuscular or intravenous injection technology;
the saccular blind end allows the common intramuscular injection needle, the subcutaneous injection needle or the intravenous infusion needle to inject the medicine into the saccular blind end buried under the skin,
the user can implant the opening end into a deep treatment target point according to the implantation mode of the traditional drainage tube, and then the saccular blind end is buried under the skin; after operation, the medicine can be injected into the saccular blind end buried under the skin by using a common intramuscular injection needle, a subcutaneous injection needle or an intravenous transfusion needle and adopting a simple subcutaneous, intramuscular or intravenous injection technology; the medicine injected into the saccular blind end enters a deep treatment target point through the drainage tube, so as to achieve the effect of accurate treatment; the saccular blind end of the continuous administration saccular pipe system is buried under the skin, no external part exists, and the risk of deep infection caused by external bacteria entering the body through the external port of the drainage pipe is reduced.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011451940.4A CN112569457B (en) | 2020-12-10 | 2020-12-10 | Continuous administration cyst tube system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011451940.4A CN112569457B (en) | 2020-12-10 | 2020-12-10 | Continuous administration cyst tube system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112569457A CN112569457A (en) | 2021-03-30 |
| CN112569457B true CN112569457B (en) | 2024-02-13 |
Family
ID=75131229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011451940.4A Active CN112569457B (en) | 2020-12-10 | 2020-12-10 | Continuous administration cyst tube system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112569457B (en) |
Citations (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1130743A (en) * | 1956-08-30 | 1957-02-11 | Flexible containers | |
| US3796217A (en) * | 1972-03-10 | 1974-03-12 | Hydr Med Sciences Inc | Drug release system |
| US5688237A (en) * | 1995-05-04 | 1997-11-18 | Cedars-Sinai Medical Center | Implantable catheter and method of use |
| US5773019A (en) * | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
| CN2362514Y (en) * | 1998-11-03 | 2000-02-09 | 陈军 | Embedding type medicine introducing device |
| US20030014036A1 (en) * | 2001-06-12 | 2003-01-16 | Varner Signe Erickson | Reservoir device for intraocular drug delivery |
| US20030078550A1 (en) * | 2001-10-22 | 2003-04-24 | Williamson Shobha Devi | Implantable pump catheter access port denial device |
| US20030171401A1 (en) * | 1999-03-18 | 2003-09-11 | Johnson Randolph Mellus | Devices and methods for pain management |
| CN2712349Y (en) * | 2004-07-12 | 2005-07-27 | 郑士全 | Subcutaneous implantable sustained-release silica gel rod for antipsychotics |
| CN1787844A (en) * | 2003-05-29 | 2006-06-14 | 瑞尼斯豪公司 | Implantable pump |
| CN200998518Y (en) * | 2006-11-03 | 2008-01-02 | 刘爱军 | Micro-wound implanting type radiotherapy bursa |
| CN101224315A (en) * | 2007-12-28 | 2008-07-23 | 李楠 | Infusion method of multiple medicine and velocity and device thereof |
| WO2009125181A1 (en) * | 2008-04-08 | 2009-10-15 | Epsom And St Helier University Hospitals Nhs Trust | Subcutaneous port and catheter |
| US20110208122A1 (en) * | 2010-02-22 | 2011-08-25 | Avraham Shekalim | Slow release liquid drug delivery device |
| CN104857622A (en) * | 2015-06-10 | 2015-08-26 | 徐增良 | Drainage tube |
| CN106470731A (en) * | 2014-03-27 | 2017-03-01 | 贝塔O2技术有限公司 | Implantable medical device |
| US20170095653A1 (en) * | 2015-10-06 | 2017-04-06 | The Johns Hopkins University | Universal microport |
| CN107735142A (en) * | 2015-04-07 | 2018-02-23 | 伊哈卜·萨阿卜 | Implanted fluid delivery system |
| CN107753418A (en) * | 2017-11-20 | 2018-03-06 | 中国农业科学院北京畜牧兽医研究所 | Medicament slow release implants and heeling-in device |
| CN108042899A (en) * | 2018-01-24 | 2018-05-18 | 山东百多安医疗器械有限公司 | A kind of dual valve implantable drug delivery system |
| CN110841134A (en) * | 2018-08-20 | 2020-02-28 | 张海军 | Automatic drug delivery system for treating Parkinson's disease |
| KR20200032023A (en) * | 2019-12-06 | 2020-03-25 | 주식회사 유니메딕스 | Patient controlled drug administration device |
| CN214633242U (en) * | 2020-12-10 | 2021-11-09 | 北京大学第三医院（北京大学第三临床医学院） | Fully-implanted deep continuous administration silicone capsule tube system |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003208901A1 (en) * | 2002-02-01 | 2003-09-02 | The Cleveland Clinic Foundation | Microinfusion device |
| US10307581B2 (en) * | 2005-04-27 | 2019-06-04 | C. R. Bard, Inc. | Reinforced septum for an implantable medical device |
| US20090149838A1 (en) * | 2007-12-10 | 2009-06-11 | Cassada David C | Subcutaneous Implant System |
-
2020
- 2020-12-10 CN CN202011451940.4A patent/CN112569457B/en active Active
Patent Citations (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1130743A (en) * | 1956-08-30 | 1957-02-11 | Flexible containers | |
| US3796217A (en) * | 1972-03-10 | 1974-03-12 | Hydr Med Sciences Inc | Drug release system |
| US5688237A (en) * | 1995-05-04 | 1997-11-18 | Cedars-Sinai Medical Center | Implantable catheter and method of use |
| US5773019A (en) * | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
| CN2362514Y (en) * | 1998-11-03 | 2000-02-09 | 陈军 | Embedding type medicine introducing device |
| US20030171401A1 (en) * | 1999-03-18 | 2003-09-11 | Johnson Randolph Mellus | Devices and methods for pain management |
| US20030014036A1 (en) * | 2001-06-12 | 2003-01-16 | Varner Signe Erickson | Reservoir device for intraocular drug delivery |
| US20030078550A1 (en) * | 2001-10-22 | 2003-04-24 | Williamson Shobha Devi | Implantable pump catheter access port denial device |
| CN1787844A (en) * | 2003-05-29 | 2006-06-14 | 瑞尼斯豪公司 | Implantable pump |
| CN2712349Y (en) * | 2004-07-12 | 2005-07-27 | 郑士全 | Subcutaneous implantable sustained-release silica gel rod for antipsychotics |
| CN200998518Y (en) * | 2006-11-03 | 2008-01-02 | 刘爱军 | Micro-wound implanting type radiotherapy bursa |
| CN101224315A (en) * | 2007-12-28 | 2008-07-23 | 李楠 | Infusion method of multiple medicine and velocity and device thereof |
| WO2009125181A1 (en) * | 2008-04-08 | 2009-10-15 | Epsom And St Helier University Hospitals Nhs Trust | Subcutaneous port and catheter |
| US20110208122A1 (en) * | 2010-02-22 | 2011-08-25 | Avraham Shekalim | Slow release liquid drug delivery device |
| CN106470731A (en) * | 2014-03-27 | 2017-03-01 | 贝塔O2技术有限公司 | Implantable medical device |
| CN107735142A (en) * | 2015-04-07 | 2018-02-23 | 伊哈卜·萨阿卜 | Implanted fluid delivery system |
| CN104857622A (en) * | 2015-06-10 | 2015-08-26 | 徐增良 | Drainage tube |
| US20170095653A1 (en) * | 2015-10-06 | 2017-04-06 | The Johns Hopkins University | Universal microport |
| CN107753418A (en) * | 2017-11-20 | 2018-03-06 | 中国农业科学院北京畜牧兽医研究所 | Medicament slow release implants and heeling-in device |
| CN108042899A (en) * | 2018-01-24 | 2018-05-18 | 山东百多安医疗器械有限公司 | A kind of dual valve implantable drug delivery system |
| CN110841134A (en) * | 2018-08-20 | 2020-02-28 | 张海军 | Automatic drug delivery system for treating Parkinson's disease |
| KR20200032023A (en) * | 2019-12-06 | 2020-03-25 | 주식회사 유니메딕스 | Patient controlled drug administration device |
| CN214633242U (en) * | 2020-12-10 | 2021-11-09 | 北京大学第三医院（北京大学第三临床医学院） | Fully-implanted deep continuous administration silicone capsule tube system |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112569457A (en) | 2021-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8512292B2 (en) | Infiltration cannula | |
| US8246587B2 (en) | Infiltration cannula | |
| US20080215010A1 (en) | Apparatus and method for using an intraosseous space for moving fluid into and out of the body | |
| JPH07303697A (en) | Port cannula device | |
| US20040034329A1 (en) | Devices and methods for infusing a liquid into a catheter | |
| JP2007513690A (en) | Flash syringe with backflow prevention stopper | |
| KR200475695Y1 (en) | Stop Cock Type Multi-Way Connector Device For Intravenous Injection With Reduced Injection Resistance | |
| CN209771078U (en) | drug delivery device | |
| CN206007700U (en) | A kind of full-implantation type venous transfusion port | |
| CN214633242U (en) | Fully-implanted deep continuous administration silicone capsule tube system | |
| CN112569457B (en) | Continuous administration cyst tube system | |
| CN205672339U (en) | Conduction catheter in a kind of three chamber urethras | |
| JP2018527131A5 (en) | ||
| CN215426894U (en) | Bladder cancer postoperative perfusion device | |
| WO2010041084A1 (en) | Medical device | |
| JP2004503336A (en) | Apparatus and method for injecting liquid into a catheter | |
| CN209713828U (en) | Two-chamber venous transfusion port | |
| US20070073239A1 (en) | Catheter device | |
| CN214911512U (en) | Disposable low-pressure enemator | |
| WO2006108336A1 (en) | Implantable administrating catheter | |
| US10420923B1 (en) | Method and device for intrathecal administering of immunoglobulin | |
| CN110180054A (en) | A kind of closed loop drug delivery systems | |
| CN213787681U (en) | External device for extracting cerebrospinal fluid through Ommaya sac and injecting medicine in sheath | |
| CN210992162U (en) | Closed bladder perfusion apparatus | |
| CN217187468U (en) | Implanted local drug delivery device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |